- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Stem Cells International
Volume 2013 (2013), Article ID 262438, 7 pages
Perspectives on the Use of Stem Cells for Autism Treatment
1Department of Experimental Medicine, Second University of Naples, Via S. Maria di Costantinopoli, 16-80138 Napoli, Italy
2Centre for Autism, La Forza del Silenzio, 81036 Caserta, Italy
3Cancellautismo, 50132 Florence, Italy
4International Child Development Resource Center, Chateau Élan, Braselton, GA 30517, USA
5Clinical Department, Cell Therapy Center EmCell, Kiev 04073, Ukraine
6Biomedical Centre for Autism Research and Treatment, 70126 Bari, Italy
Received 10 May 2013; Revised 22 August 2013; Accepted 6 September 2013
Academic Editor: Chen Lin
Copyright © 2013 Dario Siniscalco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing, Arlington, Va, USA, 4th edition, 2000.
- K. Williams, D. M. Wheeler, N. Silove, and P. Hazell, “Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD),” Cochrane Database of Systematic Reviews, vol. 8, Article ID CD004677, 2010.
- J. Blake, H. E. Hoyme, and P. L. Crotwell, “A brief history of autism, the autism/vaccine hypothesis and a review of the genetic basis of autism spectrum disorders,” South Dakota Medicine, no. 58–65, 2013.
- J. J. Bradstreet, S. Smith, M. Baral, and D. A. Rossignol, “Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder,” Alternative Medicine Review, vol. 15, no. 1, pp. 15–32, 2010.
- X. Ming, M. Brimacombe, J. Chaaban, B. Zimmerman-Bier, and G. C. Wagner, “Autism spectrum disorders: concurrent clinical disorders,” Journal of Child Neurology, vol. 23, no. 1, pp. 6–13, 2008.
- J. T. McCracken, “Safety issues with drug therapies for autism spectrum disorders,” Journal of Clinical Psychiatry, vol. 66, supplement 10, pp. 32–37, 2005.
- D. Coury, “Medical treatment of autism spectrum disorders,” Current Opinion in Neurology, vol. 23, no. 2, pp. 131–136, 2010.
- D. Siniscalco and N. Antonucci, “Possible use of Trichuris suis ova in autism spectrum disorders therapy,” Medical Hypotheses, vol. 81, no. 1, pp. 1–4, 2013.
- D. Siniscalco, A. Sapone, A. Cirillo, C. Giordano, S. Maione, and N. Antonucci, “Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 480289, 6 pages, 2012.
- D. Siniscalco, A. Giordano, and U. Galderisi, “Novel insights in basic and applied stem cell therapy,” Journal of Cellular Physiology, vol. 227, no. 5, pp. 2283–2286, 2012.
- D. Siniscalco, A. Pandolfi, and U. Galderisi, “State-of-the-art on basic and applied stem cell therapy; Stem Cell Research Italy-International Society for Cellular Therapy Europe, Joint Meeting, Montesilvano (PE)-Italy, June 10–12, 2011,” Stem Cells and Development, vol. 21, no. 5, pp. 668–669, 2012.
- D. Siniscalco, “Stem cell research: an opportunity for autism spectrum disorders treatment,” Autism, vol. 2, no. 2, article e106, 2012.
- S. Razavi, M. R. Razavi, H. Zarkesh Esfahani, M. Kazemi, and F. S. Mostafavi, “Comparing brain-derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow-derived stem cells,” Development, Growth & Differentiation, vol. 55, no. 6, pp. 648–655, 2013.
- D. Drago, C. Cossetti, N. Iraci et al., “The stem cell secretome and its role in brain repair,” Biochimie, 2013.
- G. P. Zheng, M. H. Ge, Q. Shu, M. Rojas, and J. Xu, “Mesenchymal stem cells in the treatment of pediatric diseases,” World Journal of Pediatrics, vol. 9, no. 3, pp. 197–211, 2013.
- D. Siniscalco, C. Giordano, U. Galderisi et al., “Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice,” Frontiers in Integrative Neuroscience, vol. 5, article 79, 2011.
- V. I. Zemel'ko, I. B. Kozhukharova, L. L. Alekseenko et al., “Neurogenic potential of human mesenchymal stem cells isolated from bone marrow, adipose tissue and endometrium: a comparative study,” Tsitologiia, vol. 55, no. 2, pp. 101–110, 2013.
- D. Siniscalco, A. Sapone, C. Giordano et al., “The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients,” Journal of Autism and Developmental Disorders, vol. 42, no. 7, pp. 1403–1410, 2012.
- O. Yabut and H. S. Bernstein, “The promise of human embryonic stem cells in aging-associated diseases,” Aging, vol. 3, no. 5, pp. 494–508, 2011.
- M. Evans, “Discovering pluripotency: 30 years of mouse embryonic stem cells,” Nature Reviews Molecular Cell Biology, vol. 12, no. 10, pp. 680–686, 2011.
- M. F. Pera, B. Reubinoff, and A. Trounson, “Human embryonic stem cells,” Journal of Cell Science, vol. 113, part 1, pp. 5–10, 2000.
- C. Tang, I. L. Weissman, and M. Drukker, “Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives,” Methods in Molecular Biology, vol. 1029, pp. 17–31, 2013.
- S. A. Jackson, J. Schiesser, E. G. Stanley, and A. G. Elefanty, “Differentiating embryonic stem cells pass through ‘temporal windows’ that mark responsiveness to exogenous and paracrine mesendoderm inducing signals,” PLoS ONE, vol. 5, no. 5, Article ID e10706, 2010.
- E. S. Ng, R. P. Davis, L. Azzola, E. G. Stanley, and A. G. Elefanty, “Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation,” Blood, vol. 106, no. 5, pp. 1601–1603, 2005.
- Y. Nakamura, T. Hiroyama, K. Miharada, and R. Kurita, “Red blood cell production from immortalized progenitor cell line,” International Journal of Hematology, vol. 93, no. 1, pp. 5–9, 2011.
- S. Senju, S. Hirata, Y. Motomura et al., “Pluripotent stem cells as source of dendritic cells for immune therapy,” International Journal of Hematology, vol. 91, no. 3, pp. 392–400, 2010.
- D. Siniscalco, C. Giordano, U. Galderisi et al., “Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice,” Cellular and Molecular Life Sciences, vol. 67, no. 4, pp. 655–669, 2010.
- M. Aleckovic and C. Simón, “Is teratoma formation in stem cell research a characterization tool or a window to developmental biology?” Reproductive Biomedicine Online, vol. 17, no. 2, pp. 270–280, 2008.
- B. Blum and N. Benvenisty, “The tumorigenicity of human embryonic stem cells,” Advances in Cancer Research, vol. 100, pp. 133–158, 2008.
- C. Leeb, M. Jurga, C. Mcguckin et al., “New perspectives in stem cell research: beyond embryonic stem cells,” Cell Proliferation, vol. 44, supplement 1, pp. 9–14, 2011.
- J. Aznar and J. L. Sánchez, “Embryonic stem cells: are useful in clinic treatments?” Journal of Physiology and Biochemistry, vol. 67, no. 1, pp. 141–144, 2011.
- E. Callaway, “Stem cells that are pure enough for the clinic,” Nature, 2011.
- C. Dennis, “Clinical-use stem cells made in Singapore,” Nature, 2006.
- C. Lok, “Stem-cell research: never say die,” Nature, vol. 481, no. 7380, pp. 130–133, 2012.
- M. F. Pera, “Stem cells: the dark side of induced pluripotency,” Nature, vol. 471, no. 7336, pp. 46–47, 2011.
- P. A. Klemmt, V. Vafaizadeh, and B. Groner, “The potential of amniotic fluid stem cells for cellular therapy and tissue engineering,” Expert Opinion on Biological Therapy, vol. 11, no. 10, pp. 1297–1314, 2011.
- E. Galende, I. Karakikes, L. Edelmann et al., “Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells,” Cellular Reprogramming, vol. 12, no. 2, pp. 117–125, 2010.
- R. Laguna Goya, R. Busch, R. Mathur, A. J. Coles, and R. A. Barker, “Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation,” Neurobiology of Disease, vol. 41, no. 2, pp. 407–414, 2011.
- P.-M. Chen, M.-L. Yen, K.-J. Liu, H.-K. Sytwu, and B.-L. Yen, “Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells,” Journal of Biomedical Science, vol. 18, no. 1, article 49, 2011.
- H. Abdulrazzak, D. Moschidou, G. Jones, and P. V. Guillot, “Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues,” Journal of the Royal Society Interface, vol. 7, supplement 6, pp. S689–S706, 2010.
- P. V. Guillot, C. Gotherstrom, J. Chan, H. Kurata, and N. M. Fisk, “Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC,” Stem Cells, vol. 25, no. 3, pp. 646–654, 2007.
- T. Piroth, M. C. Pauly, C. Schneider et al., “Transplantation of human fetal tissue for neurodegenerative diseases: validation of a new protocol for microbiological analysis and bacterial decontamination,” Cell Transplantation, 2013.
- S. Uchida, Y. Inanaga, M. Kobayashi, S. Hurukawa, M. Araie, and N. Sakuragawa, “Neurotrophic function of conditioned medium from human amniotic epithelial cells,” Journal of Neuroscience Research, vol. 62, pp. 585–590, 2000.
- N. Sakuragawa, M. A. Elwan, S. Uchida, T. Fujii, and K. Kawashima, “Non-neuronal neurotransmitters and neurotrophic factors in amniotic epithelial cells: expression and function in humans and monkey,” Japanese Journal of Pharmacology, vol. 85, no. 1, pp. 20–23, 2001.
- H.-C. Pan, D.-Y. Yang, S.-P. Ho et al., “Escalated regeneration in sciatic nerve crush injury by the combined therapy of human amniotic fluid mesenchymal stem cells and fermented soybean extracts, Natto,” Journal of Biomedical Science, vol. 16, no. 1, article 75, 2009.
- D. Siniscalco, “Transplantation of human mesenchymal stem cells in the study of neuropathic pain,” Methods in Molecular Biology, vol. 617, pp. 337–345, 2010.
- A. Arthur, A. Zannettino, and S. Gronthos, “The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair,” Journal of Cellular Physiology, vol. 218, no. 2, pp. 237–245, 2009.
- G. Brooke, M. Cook, C. Blair et al., “Therapeutic applications of mesenchymal stromal cells,” Seminars in Cell and Developmental Biology, vol. 18, no. 6, pp. 846–858, 2007.
- B. Short, N. Brouard, T. Occhiodoro-Scott, A. Ramakrishnan, and P. J. Simmons, “Mesenchymal stem cells,” Archives of Medical Research, vol. 34, no. 6, pp. 565–571, 2003.
- N. Beyer Nardi and L. da Silva Meirelles, “Mesenchymal stem cells: isolation, in vitro expansion and characterization,” Handbook of Experimental Pharmacology, no. 174, pp. 249–282, 2006.
- P. S. Frenette, S. Pinho, D. Lucas, and C. Scheiermann, “Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine,” Annual Review of Immunology, vol. 31, pp. 285–316, 2013.
- M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.
- P. Bernstein, I. Sperling, D. Corbeil, U. Hempel, and S. Fickert, “Progenitor cells from cartilage—no osteoarthritis-grade-specific differences in stem cell marker expression,” Biotechnology Progress, vol. 29, no. 1, pp. 206–212, 2013.
- S. Huang, V. Leung, S. Peng et al., “Developmental definition of MSCs: new insights into pending questions,” Cellular Reprogramming, vol. 13, no. 6, pp. 465–472, 2011.
- L. Pascucci, G. Curina, F. Mercati et al., “Flow cytometric characterization of culture expanded multipotent mesenchymal stromal cells (MSCs) from horse adipose tissue: towards the definition of minimal stemness criteria,” Veterinary Immunology and Immunopathology, vol. 144, no. 3-4, pp. 499–506, 2011.
- D. Siniscalco, N. Sullo, S. Maione, F. Rossi, and B. D'Agostino, “Stem cell therapy: the great promise in lung disease,” Therapeutic Advances in Respiratory Disease, vol. 2, no. 3, pp. 173–177, 2008.
- K. Le Blanc and M. F. Pittenger, “Mesenchymal stem cells: progress toward promise,” Cytotherapy, vol. 7, no. 1, pp. 36–45, 2005.
- C. E. Petrie Aronin and R. S. Tuan, “Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells,” Birth Defects Research C, vol. 90, no. 1, pp. 67–74, 2010.
- T. Meyerrose, S. Olson, S. Pontow et al., “Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors,” Advanced Drug Delivery Reviews, vol. 62, no. 12, pp. 1167–1174, 2010.
- P. A. Sotiropoulou and M. Papamichail, “Immune properties of mesenchymal stem cells,” Methods in Molecular Biology, vol. 407, pp. 225–243, 2007.
- R. E. Newman, D. Yoo, M. A. LeRoux, and A. Danilkovitch-Miagkova, “Treatment of inflammatory diseases with mesenchymal stem cells,” Inflammation and Allergy—Drug Targets, vol. 8, no. 2, pp. 110–123, 2009.
- K. Ksi̧zek, “A comprehensive review on mesenchymal stem cell growth and senescence,” Rejuvenation Research, vol. 12, no. 2, pp. 105–116, 2009.
- M. K. Majumdar, M. A. Thiede, J. D. Mosca, M. Moorman, and S. L. Gerson, “Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells,” Journal of Cellular Physiology, vol. 176, pp. 57–66, 1998.
- L. da Silva Meirelles, A. M. Fontes, D. T. Covas, and A. I. Caplan, “Mechanisms involved in the therapeutic properties of mesenchymal stem cells,” Cytokine and Growth Factor Reviews, vol. 20, no. 5-6, pp. 419–427, 2009.
- M. Giuliani, M. Fleury, A. Vernochet et al., “Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation,” PLoS ONE, vol. 6, no. 5, Article ID e19988, 2011.
- M. J. Hoogduijn, F. Popp, R. Verbeek et al., “The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy,” International Immunopharmacology, vol. 10, no. 12, pp. 1496–1500, 2010.
- F. Dazzi and F. M. Marelli-Berg, “Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells,” European Journal of Immunology, vol. 38, no. 6, pp. 1479–1482, 2008.
- R. Tatara, K. Ozaki, Y. Kikuchi et al., “Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation,” Cytotherapy, vol. 13, no. 6, pp. 689–694, 2011.
- P. Ashwood, B. A. Corbett, A. Kantor, H. Schulman, J. van de Water, and D. G. Amaral, “In search of cellular immunophenotypes in the blood of children with autism,” PLoS ONE, vol. 6, no. 5, Article ID e19299, 2011.
- K. Suzuki, H. Matsuzaki, K. Iwata et al., “Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders,” PLoS ONE, vol. 6, no. 5, Article ID e20470, 2011.
- S. Gupta, D. Samra, and S. Agrawal, “Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin,” Journal of Clinical Immunology, vol. 30, no. 1, pp. S90–S96, 2010.
- A. M. Enstrom, C. E. Onore, J. A. van de Water, and P. Ashwood, “Differential monocyte responses to TLR ligands in children with autism spectrum disorders,” Brain, Behavior, and Immunity, vol. 24, no. 1, pp. 64–71, 2010.
- D. Siniscalco, A. Sapone, C. Giordano et al., “Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders,” Journal of Autism and Developmental Disorders, 2013.
- A. L. Oblak, D. L. Rosene, T. L. Kemper, M. L. Bauman, and G. J. Blatt, “Altered posterior cingulate cortical cyctoarchitecture, but normal density of neurons and interneurons in the posterior cingulate cortex and fusiform gyrus in autism,” Autism Research, vol. 4, no. 3, pp. 200–211, 2011.
- E. R. Whitney, T. L. Kemper, D. L. Rosene, M. L. Bauman, and G. J. Blatt, “Density of cerebellar basket and stellate cells in autism: evidence for a late developmental loss of Purkinje cells,” Journal of Neuroscience Research, vol. 87, no. 10, pp. 2245–2254, 2009.
- E. Courchesne, C. M. Karns, H. R. Davis et al., “Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study,” Neurology, vol. 57, no. 2, pp. 245–254, 2001.
- M. L. Bauman and T. L. Kemper, “Neuroanatomic observations of the brain in autism: a review and future directions,” International Journal of Developmental Neuroscience, vol. 23, no. 2-3, pp. 183–187, 2005.
- R. C. Rodrigues Hell, M. M. Silva Costa, A. M. Goes, and A. L. R. Oliveira, “Local injection of BDNF producing mesenchymal stem cells increases neuronal survival and synaptic stability following ventral root avulsion,” Neurobiology of Disease, vol. 33, no. 2, pp. 290–300, 2009.
- Y.-K. Chang, M.-H. Chen, Y.-H. Chiang et al., “Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells,” Journal of Biomedical Science, vol. 18, no. 1, article 54, 2011.
- L. Li and J. Jiang, “Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms,” Frontiers of Medicine in China, vol. 5, no. 1, pp. 33–39, 2011.
- K. Miyake, T. Hirasawa, T. Koide, and T. Kubota, “Epigenetics in autism and other neurodevelopmental diseases,” Advances in Experimental Medicine and Biology, vol. 724, pp. 91–98, 2012.
- M. Witkowska-Zimny and K. Walenko, “Stem cells from adipose tissue,” Cellular and Molecular Biology Letters, vol. 16, no. 2, pp. 236–257, 2011.
- M. Locke, V. Feisst, and P. R. Dunbar, “Concise review: human adipose-derived stem cells: separating promise from clinical need,” Stem Cells, vol. 29, no. 3, pp. 404–411, 2011.
- M. Witkowska-Zimny and E. Wrobel, “Perinatal sources of mesenchymal stem cells: Wharton's jelly, amnion and chorion,” Cellular and Molecular Biology Letters, vol. 16, no. 3, pp. 493–514, 2011.
- C. Zhou, B. Yang, Y. Tian et al., “Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes,” Cellular Immunology, vol. 272, no. 1, pp. 33–38, 2011.
- M. M. Carvalho, F. G. Teixeira, R. L. Reis, N. Sousa, and A. J. Salgado, “Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine,” Current Stem Cell Research and Therapy, vol. 6, no. 3, pp. 221–228, 2011.
- Y.-C. Hsu, D.-C. Lee, and I.-M. Chiu, “Neural stem cells, neural progenitors, and neurotrophic factors,” Cell Transplantation, vol. 16, no. 2, pp. 133–150, 2007.
- H. E. Stevens, K. M. Smith, B. G. Rash, and F. M. Vaccarino, “Neural stem cell regulation, fibroblast growth factors, and the developmental origins of neuropsychiatric disorders,” Frontiers in Neuroscience, vol. 4, article 59, 2010.
- J. D. Buxbaum, “Multiple rare variants in the etiology of autism spectrum disorders,” Dialogues in Clinical Neuroscience, vol. 11, no. 1, pp. 35–43, 2009.
- G. Martino, M. Bacigaluppi, and L. Peruzzotti-Jametti, “Therapeutic stem cell plasticity orchestrates tissue plasticity,” Brain, vol. 134, part 6, pp. 1585–1587, 2011.